MYXOFIBROSARCOMA
Clinical trials for MYXOFIBROSARCOMA explained in plain language.
Never miss a new study
Get alerted when new MYXOFIBROSARCOMA trials appear
Sign up with your email to follow new studies for MYXOFIBROSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for rare sarcomas
Disease control CompletedThis study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy boosts chemo against rare sarcomas?
Disease control CompletedThis study tested whether adding an immunotherapy drug called APX005M to standard chemotherapy (doxorubicin) could help shrink tumors in people with advanced soft tissue sarcoma. 27 adults with certain sarcoma types took part. The goal was to see if the combination was safe and w…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE2 • Sponsor: Alexander Z. Wei, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Personalized chemo shows promise against rare sarcomas
Disease control CompletedThis Phase 3 trial tested whether giving chemotherapy based on the specific type of soft tissue sarcoma works better than a one-size-fits-all approach. 550 adults with high-risk sarcomas in the arms or trunk were randomly assigned to standard chemo or a chemo regimen matched to t…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE3 • Sponsor: Italian Sarcoma Group • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental drug combo targets Hard-to-Treat sarcomas
Disease control CompletedThis study tested a new drug called mecbotamab vedotin, alone or with the immunotherapy nivolumab, in 245 adults and teens aged 12+ with advanced solid tumors, including sarcomas. The goal was to check safety and see if the drug shrinks tumors. The trial is now complete, and resu…
Matched conditions: MYXOFIBROSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC